![Eric Viaud](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Eric Viaud
Algemeen Directeur bij Gene Signal International SA
Actieve functies van Eric Viaud
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Arterial Remodelling Technologies SA
![]() Arterial Remodelling Technologies SA Pharmaceuticals: MajorHealth Technology Arterial Remodelling Technologies SA develops bioresorbable peripheral and coronary polymer stents. Its products includes ART PBS scaffold, procedure and Clinical data. The company was founded by Antoine Lafont, Michel Vert and J. Frederick Cornhill in 2001 and is headquartered in Paris, France. | Voorzitter | 18-11-2009 | - |
Gene Signal SAS
![]() Gene Signal SAS Pharmaceuticals: GenericHealth Technology Gene Signal is a research based biotechnology company specialized in the discovery, development, and commercialization of a new class of oligonucleotides, proteins and monoclonal antibodies to treat a range of conditions where angiogenesis plays a determinant role. The company's innovative therapies use precisely targeted angiogenic (inducing vascular growth) or angiostatic (inhibiting vascular growth) agents, derived from genes that are exclusively involved with the angiogenesis process . The firm's therapies aim to provide a more targeted alternative to existing solutions like Vascular Endothelial Growth Factors which impact other physiological phenomena in addition to angiogenesis. Gene Signal's targeted therapies represents a novel, next-generation approach to the management of angiogenesis based conditions and offer the potential to improve treatment options for concerned patients. Founded in 2000, Gene Signal has assembled an strong leadership team that includes scientific, medical, regulatory, and business professionals with successful track records in developing and bringing to market state of the art drugs. Gene Signal continues to develop its angiogenesis modulating technology and has built a significant intellectual property portfolio, as well as a robust clinical and preclinical pipeline. | Algemeen Directeur | 01-01-2000 | - |
Voorzitter | 17-09-2009 | - | |
Oprichter | 01-01-2000 | - | |
Gene Signal International SA
![]() Gene Signal International SA Pharmaceuticals: MajorHealth Technology Gene Signal International SA engages in the development of drugs to manage angiogenesis based conditions. It is a research based biotechnology company specialized in the discovery, development, and commercialization of a new class of oligonucleotides, proteins and monoclonal antibodies to treat a range of conditions where angiogenesis plays a determinant role. The company was founded by Eric Viaud, Salman Al-Mahmood, and Eric Thorin in 2000 and is headquartered in Lausanne, Switzerland. | Algemeen Directeur | 01-01-2000 | - |
Voorzitter | 23-09-2010 | - | |
Oprichter | 01-01-2000 | - | |
Aterovax SA
![]() Aterovax SA Medical/Nursing ServicesHealth Services Aterovax SA develops in vitro diagnostic products for the management and assessment of cardiovascular diseases. Its products include diagnostic blood tests for determining and measuring activity of the cardiovascular biomarkers secretory phospholipase A2 (sPLA2) and secretory phospholipase A2-IIA (sPLA2-IIA) which provide physicians clinical information about the presence of a destabilized atherosclerotic plaque. The company was founded by Alain Tedgui, Ziad Mallat, Philippe Gabriel Steg, Joelle Benessiano and Jean-Marie Freyssinet on June 29, 2006 and is headquartered in Paris, France. | Directeur/Bestuurslid | 16-08-2006 | - |
Société Petroliere du Bec d'Ambes
![]() Société Petroliere du Bec d'Ambes Miscellaneous Commercial ServicesCommercial Services Société Petroliere du Bec d'Ambes provides refrigerated storage facility services. The company is headquartered in Carbon-Blanc, France. | Algemeen Directeur | - | - |
Loopbaan van Eric Viaud
Eerdere bekende functies van Eric Viaud
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
BASF France SAS
![]() BASF France SAS Chemicals: Major DiversifiedProcess Industries BASF France manufactures and markets coating products. The company is headquartered in Levallois-Perret, France. | Corporate Officer/Principal | - | - |
Medtronic France SAS
![]() Medtronic France SAS Medical/Nursing ServicesHealth Services Medtronic France SAS provides medical equipment and medical technology services. The company was founded by Earl Bakken and Palmer Hermundslie in 1949 and is headquartered in Boulogne-Billancourt, France. | Corporate Officer/Principal | - | - |
Astra Zeneca Holding France SAS
![]() Astra Zeneca Holding France SAS Pharmaceuticals: MajorHealth Technology Astra Zeneca Holding France SAS operates as a holding firm with interest in pharmaceuticals. The company was founded in 1994 and is headquartered in Rueil-Malmaison, France. | Corporate Officer/Principal | - | - |
Opleiding van Eric Viaud
Université de Bordeaux | Graduate Degree |
Statistieken
Internationaal
Frankrijk | 9 |
Zwitserland | 2 |
Operationeel
Chairman | 3 |
Chief Executive Officer | 3 |
Corporate Officer/Principal | 3 |
Sectoraal
Health Technology | 5 |
Health Services | 3 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 8 |
---|---|
Arterial Remodelling Technologies SA
![]() Arterial Remodelling Technologies SA Pharmaceuticals: MajorHealth Technology Arterial Remodelling Technologies SA develops bioresorbable peripheral and coronary polymer stents. Its products includes ART PBS scaffold, procedure and Clinical data. The company was founded by Antoine Lafont, Michel Vert and J. Frederick Cornhill in 2001 and is headquartered in Paris, France. | Health Technology |
Gene Signal SAS
![]() Gene Signal SAS Pharmaceuticals: GenericHealth Technology Gene Signal is a research based biotechnology company specialized in the discovery, development, and commercialization of a new class of oligonucleotides, proteins and monoclonal antibodies to treat a range of conditions where angiogenesis plays a determinant role. The company's innovative therapies use precisely targeted angiogenic (inducing vascular growth) or angiostatic (inhibiting vascular growth) agents, derived from genes that are exclusively involved with the angiogenesis process . The firm's therapies aim to provide a more targeted alternative to existing solutions like Vascular Endothelial Growth Factors which impact other physiological phenomena in addition to angiogenesis. Gene Signal's targeted therapies represents a novel, next-generation approach to the management of angiogenesis based conditions and offer the potential to improve treatment options for concerned patients. Founded in 2000, Gene Signal has assembled an strong leadership team that includes scientific, medical, regulatory, and business professionals with successful track records in developing and bringing to market state of the art drugs. Gene Signal continues to develop its angiogenesis modulating technology and has built a significant intellectual property portfolio, as well as a robust clinical and preclinical pipeline. | Health Technology |
Gene Signal International SA
![]() Gene Signal International SA Pharmaceuticals: MajorHealth Technology Gene Signal International SA engages in the development of drugs to manage angiogenesis based conditions. It is a research based biotechnology company specialized in the discovery, development, and commercialization of a new class of oligonucleotides, proteins and monoclonal antibodies to treat a range of conditions where angiogenesis plays a determinant role. The company was founded by Eric Viaud, Salman Al-Mahmood, and Eric Thorin in 2000 and is headquartered in Lausanne, Switzerland. | Health Technology |
Aterovax SA
![]() Aterovax SA Medical/Nursing ServicesHealth Services Aterovax SA develops in vitro diagnostic products for the management and assessment of cardiovascular diseases. Its products include diagnostic blood tests for determining and measuring activity of the cardiovascular biomarkers secretory phospholipase A2 (sPLA2) and secretory phospholipase A2-IIA (sPLA2-IIA) which provide physicians clinical information about the presence of a destabilized atherosclerotic plaque. The company was founded by Alain Tedgui, Ziad Mallat, Philippe Gabriel Steg, Joelle Benessiano and Jean-Marie Freyssinet on June 29, 2006 and is headquartered in Paris, France. | Health Services |
Astra Zeneca Holding France SAS
![]() Astra Zeneca Holding France SAS Pharmaceuticals: MajorHealth Technology Astra Zeneca Holding France SAS operates as a holding firm with interest in pharmaceuticals. The company was founded in 1994 and is headquartered in Rueil-Malmaison, France. | Health Technology |
BASF France SAS
![]() BASF France SAS Chemicals: Major DiversifiedProcess Industries BASF France manufactures and markets coating products. The company is headquartered in Levallois-Perret, France. | Process Industries |
Medtronic France SAS
![]() Medtronic France SAS Medical/Nursing ServicesHealth Services Medtronic France SAS provides medical equipment and medical technology services. The company was founded by Earl Bakken and Palmer Hermundslie in 1949 and is headquartered in Boulogne-Billancourt, France. | Health Services |
Société Petroliere du Bec d'Ambes
![]() Société Petroliere du Bec d'Ambes Miscellaneous Commercial ServicesCommercial Services Société Petroliere du Bec d'Ambes provides refrigerated storage facility services. The company is headquartered in Carbon-Blanc, France. | Commercial Services |
- Beurs
- Insiders
- Eric Viaud
- Ervaring